Ellex Medical Lasers will increase the production capacity of its Ellex iTrack catheters to approximately 50,000 units per annum from a current level of approximately 20,000 units per annum by expanding and upgrading its manufacturing facility in Fremont, California.
In July 2017, the production capacity at Fremont was upgraded from 10,000 units per annum to 20,000 units per annum. This second stage production increase is aimed at increasing capacity to 50,000 units per annum by July 2018, adding clean room facilities in an adjacent building in Fremont and by recruiting an additional technical staff.
“We see that a production capacity of 50,000 units per year will meet projected demand for Ellex iTrack for at least the next 12 months,” said Ellex CEO, Tom Spurling.
A third stage production capacity increase to more than double the 50,000 units per annum is being planned to maintain supply for future demand.
We see that a production capacity of 50,000 units per year will meet projected demand for Ellex iTrack for at least the next 12 months
In other news, Ellex has been granted a European patent titled Retinal Rejuvenation Laser. This patent significantly strengthens the company’s expanding patent portfolio for the Ellex 2RT Laser for treatment of age-related macular degeneration.
Ellex 2RT is a non-damaging laser treatment that stimulates regeneration of the retinal pigment epithelium to preserve vision, and aims to treat the RPE before vision loss occurs.
The LEAD (Laser intervention in Early Age-related macular Degeneration) clinical trial is currently underway, with results due in mid-2018 that Ellex anticipates will validate the efficacy of Ellex 2RT.